Human Oncology & Pathogenesis Program

The Marc Ladanyi Lab

Research

Pictured: Marc Ladanyi
Marc Ladanyi, MD

The research program in this laboratory focuses on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on clinical translation of potential diagnostic markers and therapeutic targets. Dr. Ladanyi also co-directs (with Chris Sander) the Genome Data Analysis Center at Memorial Sloan Kettering, which is part of the TCGA project network.

Examples of recent contributions include the validation of DUSP4 as a driver gene for 8p losses in EGFR-mutant lung adenocarcinomas, the establishment of methods for enhanced detection of the EGFR T790M secondary mutation in the setting of acquired resistance to EGFR inhibitors, the discovery of BAP1 mutations in mesotheliomas with 3p losses, the identification of novel, recurrent HEY1-NCOA2 and KIF5B-RET fusions in mesenchymal chondrosarcoma and lung adenocarcinoma, respectively, both based on mining of exon-level expression data, as well as major involvement in the TCGA Network marker papers on the genomics of glioblastoma, ovarian carcinoma, and squamous lung cancer. Ongoing projects are addressing further questions in lung adenocarcinoma, mesothelioma, and several sarcoma types using whole exome and whole transcriptome sequencing, ChIP-seq, Sequenom mass spectrometry genotyping, NanoString expression profiling, RNAi screens, chemical screens, and proteomic approaches.

Ladanyi lab

Ladanyi lab

Publications

View All Publications

People

Pictured: Marc Ladanyi

Marc Ladanyi, MD

  • Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.
  • MD, McGill University
212-639-6369
Office Phone
View physician profile
Physician profile

Members

Jenna-Marie Dix

Molecular Diagnostics Research Coordinator

Arielle Elkrief

Research Fellow

Renate Kurth

Research Technician

Igor Odintsov

Research Scholar

Romel Somwar

Senior Research Scientist

Lab Alumni
Lab Affiliations

Open Positions

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Marc Ladanyi discloses the following relationships and financial interests:

  • ADC Therapeutics
    Provision of Services
  • AstraZeneca
    Provision of Services
  • Bayer
    Provision of Services
  • Blueprint Medicines
    Provision of Services
  • Bristol-Myers Squibb
    Provision of Services
  • Janssen Pharmaceuticals, Inc.
    Provision of Services
  • Lilly Oncology
    Provision of Services
  • Loxo Oncology
    Provision of Services
  • Merck & Co Inc.
    Provision of Services
  • Paige.AI, Inc.
    Ownership / Equity Interests; Provision of Services
  • PeerView Institute for Medical Education (PVI)
    Provision of Services
  • Riken Genesis Co., Ltd.
    Provision of Services
  • Takeda Pharmaceuticals
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures